[Specificity of the interaction of carcinogenic and cytostatic agents with the elements of the genome at different levels of its organization].
The analysis of the literature permits drawing a conclusion that according to DNA binding site-specificity carcinogens and antitumour drugs can be divided into GC- and AT-binding compounds. When interacting with eucaryotic DNA such specificity leads to an increased binding of carcinogens and antitumour drugs to the repeat-rich DNA (satellite DNA, alpha-DNA, flanking regions of genes). It is supposed that specificity of the binding of chemical compounds on higher levels of genome organization (active and inactive chromatin, nuclear matrix-bound DNA) is also defined by the affinity of compounds to GC- or AT-rich repeats.
S'iakste
N I
NI
S'iakste
T G
TG
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002273:Carcinogens / Q000494:pharmacology*; D002843:Chromatin / Q000187:drug effects / Q000235:genetics; D004247:DNA / Q000187:drug effects / Q000235:genetics; D004249:DNA Damage; D004347:Drug Interactions; D005796:Genes / Q000187:drug effects*; D006801:Humans; D009369:Neoplasms / Q000139:chemically induced / Q000235:genetics; D009374:Neoplasms, Experimental / Q000139:chemically induced / Q000235:genetics
D000970:Antineoplastic Agents; D002273:Carcinogens; D002843:Chromatin; D004247:DNA
Spetsifichnost' vzaimodeĭstviia kantserogennykh i tsitostaticheskikh agentov s élementami genoma na raznykh urovniakh ego organizatsii.